Vertex Pharmaceuticals showcased the latest results for influenza candidate VX-787 to attract partnering companies.
Vertex Pharmaceuticals announced that treatment with VX-787 in a Phase 2 influenza challenge study resulted in statistically significant improvements in viral and clinical measurements of infection.
VX-787 is an investigational new class of medicine for the treatment of influenza and is designed to directly inhibit replication of the virus.
The study met its primary endpoint, and showed a statistically significant decrease in the amount of virus in nasal secretions (viral shedding) over the seven-day study period.
Based on these data, Vertex will explore collaborative opportunities to support further development of VX-787.
Vertex Pharmaceuticals is a top biotech company, or bigbiotech company, based in Cambridge, MA, USA.
Vertex has more than 2,000 employees around the world, and for three years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences.
Read: more on Vertex Pharmaceuticals company profile, recent partnering, M&A and financing news and articles
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity